AS

Asher Bio

YC S19 ↗

San Francisco, US · 3 employees · 7 known investors

asherbio.com ↗

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity. The company is advancing etakafusp alfa, a cis-targeting IL-2 candidate, for solid tumor treatment and applying its platform to oncology and infectious disease indications.

Founders & leadership· Y Combinator alumni (S19)

ID

Ivana DjureticinFounder

AY

Andy YeunginFounder

Investors · 7

EM

Emles Venture PartnersNew York

GO

GoAhead VenturesMenlo Park · $500K – $1M

MI

Mission Bay CapitalSan Francisco

MI

Mission BiocapitalSan Francisco · $500K

RA

RA CapitalBoston

Y

Y CombinatorSan Francisco · $500K

TH

Third Rock VenturesreportedBoston · $100K – $5M